Bristol Myers to buy RayzeBio for more than 100% premium, in a deal valued at $4.1 billion

Bristol Myers Squibb Co. BMY announced Tuesday an agreement to buy radiopharmaceutical therapeutics company RayzeBio Inc. RYZB in a deal valued at $4.1 billion. Under terms of the deal, Bristol Myers will pay $62.50 in cash for each RayzeBio share outstanding, which represents a premium of 104.4% over Friday’s closing price of $30.57. RayzeBio’s stock was halted for new until 7:30 a.m. Eastern and Bristol Myers’ stock tacked on 0.2% in premarket trading. “This transaction enhances our increasingly diversified oncology portfolio by bringing a differentiated platform and pipeline, and further strengthens our growth opportunities…